Reactions 1372 - 8 Oct 2011

★ SCatumaxomab

First report of inflammatory lesions of theperitoneum following intraperitonealadministration: case report

A 54-year-old man with gastric cancer developedinflammatory lesions of the peritoneum followingtreatment with intraperitoneal catumaxomab.

The man began receiving perioperative chemotherapywith epirubicin, cisplatin and capecitabine in January 2008as part of a phase II study. In April 2008, an endoscopicultrasound revealed stomach wall thickening and evidenceof a hypoechoic mass. He underwent completegastrectomy 2 weeks later. The first dose of catumaxomabwas administered intraoperatively, followed by infusions of10, 20, 50 and 150µg on postoperative days 10, 13, 16 and19, respectively. He was scheduled to receive threeadditional cycles of adjuvant chemotherapy, but treatmentwas stopped due to grade 3 asthenia. In September 2008,an abdominal CT scan showed a 5mm lesion in segment 5of the liver, with partial thickening of the colon walls.Mesenteric decay with peritoneal carcinomatosis wassuspected. Laparoscopy revealed multiple small whitelesions in the left upper abdomen and on the surface of theright liver lobe. Histologic and immunohistochemicalinvestigations were consistent with nonmalignantinflammatory tissue. A peritoneal biopsy showedgranulation tissue lesions and submesenterial nodularfibrotic lesions. In December 2008, a follow-up CT scanshowed regression of the thickened peritoneum andhepatic lesion.

Author comment: "[W]e consider this phenomenon to bemost likely related to [intraperitoneal] treatment withcatumaxomab or an inflammatory reaction afterdiscontinuation of treatment."Russel J, et al. Inflammatory lesions of the peritoneum mimic carcinomatosis aftertreatment with intravenous chemotherapy and intraperitoneal catumaxomab.Journal of Clinical Oncology 29: e644-e646, No. 22, Aug 2011. Available from:URL: http://dx.doi.org/10.1200/jco.2010.34.3939 - Germany 803061166

» Editorial comment: A search of AdisBase, Medline andEmbase did not reveal any previous case reports ofperitoneal lesions associated with catumaxomab. The WHOADR database did not contain any reports of peritoneallesions or inflammation associated with catumaxomab.

1

Reactions 8 Oct 2011 No. 13720114-9954/10/1372-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved